Finland· FI-REL-REL64508
Pylera
A bismuth subcitrate, tetracycline and metronidazole product containing tetracycline hydrochloride + bismuth subcitrate potassium + metronidazole, registered in Finland by Laboratoires Juvise Pharmaceuticals. The same ATC class is registered in 9 of our 19 countries.
Checked against Fimea (Finland) on
Informational only — not a medical device.
Where it is registered
Bismuth subcitrate, tetracycline and metronidazole is registered in 9 of 19 countries.
Countries holding a registration under ATC A02BD08 (bismuth subcitrate, tetracycline and metronidazole), each read from that country’s own register.
- This record: Finland, from Fimea (Finland)
- 6 of them publish a price we can compare per daily dose
Bismuth subcitrate, tetracycline and metronidazole · ATC A02BD08
9 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Ireland
- Netherlands
- Polandprice
- Switzerlandprice
- United Statesprice
The record
At a glance
Fimea (Finland)- Active substance
- Tetracycline hydrochloride + Bismuth subcitrate potassium + Metronidazole
- Manufacturer
- Laboratoires Juvise Pharmaceuticals
- Country
- Finland (FI)
- ATC code
- A02BD08
- ATC class
- Bismuth subcitrate, tetracycline and metronidazole
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Bismuth subcitrate, tetracycline and metronidazole in 9 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- PolandPyleraDelfarma Sp. z o.o.
- United StatesBismuth Subcitrate Potassium, Metronidazole and Tetracycline HydrochloridePar Health USA, LLC
- GermanyPyleraLaboratoires Juvise Pharmaceuticals
- SwitzerlandPylera 140 mg/125 mg/125 mg, HartkapselnMedius AG
- IrelandPylera 140 mg/125 mg/125 mg capsules, hardLaboratoires Juvise Pharmaceuticals
- SwedenPylera 140 mg/125 mg/125 mg Kapsel, hårdLaboratoires Juvise Pharmaceuticals
- FrancePYLERA 140 mg/125 mg/125 mg, géluleLABORATOIRES JUVISE PHARMACEUTICALS
- CzechiaPYLERALaboratoires Juvisé Pharmaceuticals, Villeurbanne
Authorised across Europe · EMA
The same active substance is authorised in 22 EEA countries. Names it is sold under:
- Austria · Pylera
- Belgium · Tryplera
- Bulgaria · Pylera
- Czechia · Pylera
- Germany · Pylera
- Denmark · Pylera
- Estonia · Pylera
- Spain · Pylera
- France · Pylera
- United Kingdom (Northern Ireland) · Pylera
- Ireland · Pylera
- Italy · Pylera
- Lithuania · Pylera
- Luxembourg · Tryplera
- Latvia · Pylera
- Malta · Pylera
- Norway · Pylera
- Poland · Pylera
- Portugal · Pylera
- Romania · Pylera
- Sweden · Pylera
- Slovakia · Pylera
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/9c3ec40b-f84f-4d7c-a2fd-b4e83b49ffd7 GET /v1/drugs/9c3ec40b-f84f-4d7c-a2fd-b4e83b49ffd7?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": null,
"form": "kapseli, kova",
"route": "Suun kautta",
"ddd_unit": null,
"strength": "140 mg / 125 mg / 125 mg",
"atc_label": "vismuttisubsitraatti, metronidatsoli ja tetrasykliini",
"ma_number": "45447",
"auth_status": "Myyntilupa myönnetty",
"eu_ma_number": null,
"fimea_rel_id": "REL64508",
"authorised_at": "2026-06-08"
}See everything about bismuth subcitrate, tetracycline and metronidazole.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.